微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 25.7% | -26.09% | -9.2% | 127/159 | -1.59% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 28.3% | -16.03% | -5.58% | 122/159 | 15.28% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 29.97% | -23.08% | -14.92% | 114/159 | 32.3% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 35.23% | -8.64% | 1.33% | 109/159 | 51.78% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 34.77% | -5.07% | 3.17% | 109/159 | 22.81% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 33.7% | -11.66% | -13.51% | 113/159 | 33.25% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 38.96% | -0.71% | 1.05% | 98/159 | 51.56% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 38.56% | -10.71% | 5.28% | 108/159 | 51.39% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 36.63% | -8.12% | -4% | 108/159 | 32.56% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 38.15% | -5.71% | -2.79% | 108/159 | 38.45% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 39.24% | -7.36% | -9.12% | 101/159 | 52.78% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 43.18% | 6.99% | 8.32% | 97/159 | 53.66% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 39.86% | -1.44% | -1.47% | 98/159 | 6.2% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 40.46% | 7.1% | -4.49% | 98/159 | 21.37% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 42.36% | 15.73% | 4.96% | 92/159 | 54.28% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 40.36% | -7.67% | -0.21% | 102/159 | 55.1% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 40.44% | -13.2% | 7.06% | 91/159 | 46.78% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 37.78% | -0.08% | 3.2% | 106/159 | 47.23% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 36.61% | 17.15% | -16.26% | 93/159 | 53.99% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 43.71% | -14.08% | -6.19% | 97/159 | -145.9% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 46.6% | -21.71% | 23.25% | 76/159 | 56.36% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 37.81% | -32.3% | 20.99% | 100/159 | 54.11% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 31.25% | -34.41% | -38.58% | 95/159 | 55.23% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 50.87% | -4.72% | -14.52% | 76/159 | -1222.98% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 59.52% | 12.41% | 6.57% | 50/159 | 55.21% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 55.85% | -10.25% | 17.23% | 57/159 | 55.21% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 47.64% | -11.11% | -10.78% | 62/159 | 51.05% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 53.4% | 10.99% | 0.85% | 68/159 | -208.09% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 52.95% | 29.59% | -14.92% | 54/159 | 53.97% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 62.23% | 48.28% | 16.1% | 39/159 | 53.39% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 53.6% | 0.39% | 11.41% | 51/159 | 53.9% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 48.11% | -8.15% | 17.75% | 68/159 | 52.32% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 40.86% | -5.63% | -2.65% | 58/159 | 49% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 41.97% | 5.32% | -21.39% | 57/159 | 47.74% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 53.39% | 16.59% | 1.93% | 33/159 | 46.55% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 52.38% | 23.52% | 20.99% | 43/159 | 48.19% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 43.29% | -0.17% | 8.65% | 38/159 | 45.76% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 39.85% | -0.84% | -12.98% | 51/159 | 45.89% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 45.79% | -12.99% | 7.99% | 30/159 | 43.5% | 贝达药业 | 97.01% | 行业排名> |
| 2015-12-31 | 42.41% | 3.33% | -2.21% | 53/159 | 45.97% | 贝达药业 | 97.02% | 行业排名> |
| 2015-09-30 | 43.37% | 17.1% | 7.91% | 40/159 | 44.69% | 舒泰神 | 94.38% | 行业排名> |
| 2015-06-30 | 40.19% | 17.11% | -23.64% | 46/159 | 45% | 贝达药业 | 96.95% | 行业排名> |
| 2015-03-31 | 52.63% | 53.8% | 28.25% | 26/159 | 43.46% | 舒泰神 | 94.4% | 行业排名> |